#United States #Secaucus #Tabelecleucel #EBV+ PTLD #Pierre Fabre

Pierre Fabre Pharmaceuticals Resubmits BLA for Tabelecleucel

Pierre Fabre Pharmaceuticals Inc. (PFP) recently announced a pivotal development in oncology treatment with the resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). This application concerns tabelecleucel, a revolutionary therapy intended for the treatment of patients suffering from Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD). This condition often manifests in patients within months following solid organ or hematopoietic cell transplant, representing a serious challenge that warrants urgent therapeutic solutions.

The CEO of PFP, Adriana Herrera, emphasized the company's steadfast dedication to improving treatment options for individuals facing EBV+ PTLD, an aggressive cancer that adheres to those whose immune systems have already been compromised. Patients who find themselves in this dire situation generally experience a significantly reduced lifespan following the failure of their initial therapies—often just weeks to a few months.

The latest submission to the FDA comes in alignment with the discussions held in the Type A meeting in April 2026, highlighting a concerted effort made by PFP to meet regulatory expectations. The resubmission comprises an enriched set of clinical data sourced from the ongoing Phase 3 ALLELE study, a single-arm trial assessing tabelecleucel in adults and children aged two years and older who are dealing with relapsed or refractory EBV+ PTLD post-transplant. Additionally, it includes supporting information from expanded access programs and various clinical studies carried out in Europe.

Tabelecleucel functions as an allogeneic, off-the-shelf EBV-specific T-cell immunotherapy, specifically designed to target and combat cells infected by the Epstein-Barr virus. Its recent approval in Europe under the name EBVALLO™ marks a significant milestone for the therapy, having received marketing authorization from the European Commission in December 2022 and further approvals in the UK and Switzerland in 2023 and 2024, respectively. However, it remains an investigational therapy in the U.S. and has not yet attained FDA approval for general use, though it is currently available to eligible patients via clinical trials.

Understanding EBV+ PTLD is critical to appreciating the urgency behind this submission. It is classified as an ultra-rare and potentially lethal malignancy that can develop in individuals following transplants, significantly impacting their prognosis. Patients who undergo solid organ transplants face a lifelong risk of developing this condition, demonstrating the pressing need for novel therapies that can improve patient survival and quality of life—especially given the alarming median survival rates of approximately three weeks post-initial treatment failure for HCT patients and four months for SOT patients.

At its core, the mission of Pierre Fabre Pharmaceuticals centers around delivering groundbreaking therapies tailored to patients facing significant health challenges, especially in oncology and rare diseases where options remain scant. Born from a foundation that has exerted influence for over 70 years, PFP stands as the U.S. pharmaceutical subsidiary of Laboratoires Pierre Fabre, which prides itself on innovation and ethical pharmaceutical practices. This commitment is evident in their goal to collaborate with healthcare professionals and researchers worldwide in the continuous pursuit of effective and ethical therapies.

In conclusion, the resubmission of the BLA for tabelecleucel represents not just a regulatory step for Pierre Fabre Pharmaceuticals but also a beacon of hope for patients awaiting new treatment modalities. The ongoing collaboration with the FDA and the commitment to clinical innovation are crucial steps toward making this potentially life-saving therapy accessible to those who need it most.